EP1682135B1 - Salz eines Tetrahydropyranylcyclopentyltetrahydropyridopyridin-Derivats als CCR-2 Antagonisten - Google Patents

Salz eines Tetrahydropyranylcyclopentyltetrahydropyridopyridin-Derivats als CCR-2 Antagonisten Download PDF

Info

Publication number
EP1682135B1
EP1682135B1 EP04796120A EP04796120A EP1682135B1 EP 1682135 B1 EP1682135 B1 EP 1682135B1 EP 04796120 A EP04796120 A EP 04796120A EP 04796120 A EP04796120 A EP 04796120A EP 1682135 B1 EP1682135 B1 EP 1682135B1
Authority
EP
European Patent Office
Prior art keywords
added
trifluoromethyl
solution
mol
pyran
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP04796120A
Other languages
English (en)
French (fr)
Other versions
EP1682135A1 (de
EP1682135A4 (de
Inventor
Mark Jensen
Robert Larsen
Daniel Richard Sidler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme Ltd
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme Ltd, Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme Ltd
Publication of EP1682135A1 publication Critical patent/EP1682135A1/de
Publication of EP1682135A4 publication Critical patent/EP1682135A4/de
Application granted granted Critical
Publication of EP1682135B1 publication Critical patent/EP1682135B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • WO-A-0213824 discloses piperidine compounds bearing a cyclopentyl group as CCR-2 modulators.
  • WO-A-0076512 discloses piperidine compounds substituted by a cyclopentylmethyl group as CCR-5 and/or CCR-3 modulators.
  • the present invention provides the succinate salt of ((1R,3S)-3-isopropyl-3- ⁇ [3-(trifluoromcthyl)-7,8-dihydro-1,6-naphthridin-6(5H)-yl]carbonyl)cyclopentyl)[(3S,4S)-3-methoxytetrahydro-2H-pyran-4-yl]amine, its use in therapy and describes an efficient synthesis of it.
  • the present invention provides the succinate salt of ((1R,3S)-3-isopropyl-3- ⁇ [3-(trifluoromethyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl]carbonyl ⁇ cyclopentyl) [(3S, 4S)-3-methoxytetrahydro-2H-pyran-4-yl]amine and its use in therapy for treating, ameliorating or reducing the risk of an inflammatory and immunoregulatory disorder or disease or of rheumatoid arthritis.
  • the present invention is also dedicated to a pharmaceutical composition which comprises this compound and an inert carrier.
  • the hydrogenation step is accomplished prior to the formation of compound 2.
  • N-((1R,3S)-3-isopropyl-3- ⁇ [3-(trifluoromethyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl]carbonyl ⁇ cyclopentyl)-N-[(cis-3S,4S)-3-methoxytetrahydro-2H-pyran-4-yl]amine, 1 is synthesized by sequentially coupling three building block compounds 4, 5 and 6 (Schemes 3, 4 and 5, below).
  • compound 1 may be purified employing crystallization, either as a succinate salt or other salt such as a benzenesulfonate salt, followed by a salt break. Purification in this manner is described in the examples which follow.
  • (1R,4S)-4-aminocyclopent-2-ene-1-carboxylic acid is converted into the corresponding methyl ester by treatment with thionyl chloride in methanol.
  • Methyl (1 R ,4 S )-4-(2,5-dimethyl-1 H -pyrrol-1-yl)cyclopent-2-ene-1-carboxylate is then synthesized by reacting the (1R,4S)-4-aminocyclopent-2-ene-1-carboxylate methyl ester with 2,4-pentanedione in the presence of DIEA.
  • intermediates may be synthesized having protecting groups other than 2,5-dimethyl-1H-pyrrol-1-yl.
  • protecting group "PG 1" includes but is not limited to tert-butoxycarbonyl, benzyloxycarbonyl, alkyloxycarbonyl, allyloxycarbonyl, benzoyl, formyl, acetyl, trifluoroacetyl, 2-nitrobenzenesulfonyl, 4-nitrobenzenesulfonyl, 2,4-dinitrobenzenesulfonyl, benzyl, triphenylmethyl, imines (such as diphenylmethylene) and other protecting groups known in the art, as exemplified in Greene, T; Wuts, P. G. M. Protective Groups in Organic Synthesis, 3rd Ed., John Wiley & Sons, Inc., New York, NY 1999 .
  • Phosphorous oxychloride (POCl 3 ) is added to chilled DMF at a rate such that the temperature remained below 10 °C (approx. 1 h).
  • the reaction mixture is warmed to RT and then 3,3,3-trifluoropropanoic acid is added (exotherm to approx. 45 °C).
  • the reaction mixture is warmed to 50°C and held at this temperature for approx 4 h.
  • Upon completion of the vinamidinium formation the reaction mixture is allowed to cool to RT.
  • the reaction mixture is then added concurrently with 5 N NaOH to a solution of NaPF 6 in water cooled to 0°C.
  • the rates of addition of the two solutions are controlled such that the temperature of the aqueous slurry remains below 10 °C and the pH is between 3 and 4 (addition time takes about 2 h).
  • the resulting yellow slurry is aged for one hour at 0 °C then filtered to collect solids.
  • the filtercake is slurry washed with ice cold water (2 times) and the cake dried with nitrogen/vacuum. Typical yield 85 %.
  • a solution of the protected piperidone, for instance the BOC protected piperidone, in THF is then added to a cooled (-20 °C) solution of lithium hexamethyldisilylamide (LiN(TMS) 2 ) in THF, keeping the temperature below 10°C, to form the lithium enolate (approx 45 min).
  • the enolate solution is transferred to a chilled (-20 °C) slurry of the CF 3 DT in THF at a rate such that the internal temperature remains below -10 °C (approx 45 min). This mixture is aged for 2 h at -20°C then acetic acid is added and the mixture warmed to room temperature over 30 minutes.
  • the organic layer from the naphthyridine formation is concentrated and solvent switched to methanol.
  • HCl in IPA is then added and the mixture heated at 60 °C until the deprotection is complete (about 1 h).
  • water is added and the pH adjusted to appox 10.5.
  • IPAc is added and the layers separated.
  • the aqueous layer is back extracted with IPAc two additional times.
  • the combined organic layers are concentrated and solvent switched to IPA.
  • This IPA solution is filtered to remove inorganic salts, the filtercake washed with IPA and the combined filtrate and washes reconcentrated to a total volume of about 5 mL/g. After the free base/IPA solution to 60°C HCl in IPA is added over 30 minutes.
  • piperidones having protecting groups (“PG 2 ”) other than tert- butoxycarbonyl may also be used.
  • Other protecting groups useful in the synthesis of the naphthiridine include, but are not limited to benzyloxycarbonyl, alkyloxycarbonyl, allyloxycarbonyl, benzoyl, acetyl, formyl, trifluoroacetyl, 2-nitrobenzenesulfonyl, 4-nitrobenzenesulfonyl, 2,4-dinitrobenzenesulfonyl, N-benzyl, triphenylmethyl, and other protecting groups known in the art, as exemplified in Greene, T; Wuts, P. G. M. Protective Groups in Organic Synthesis, 3rd Ed, John Wiley & Sons, Inc., New York, NY 1999 .
  • the starting pyranone is converted to its dipropyl ketal by treatment with tripropylorthoformate in the presence of an acid catalyst.
  • the crude ketal is then heated in the presence of chlorobenzene. Under these conditions, elimination of propanol provides the propyl enol ether.
  • the reaction is driven by the removal of propanol by distillation during the reaction sequence.
  • the crude enol ether is then oxidized under modified Sharpless asymmetric dihydroxylation conditions. In this reaction N-methylmorpholine oxide is used as the stoichiometric oxidant.
  • the reaction typically gives the product ⁇ -hydroxyketone in about 80 to 85 % ee.
  • the ⁇ -hydroxyketone is not isolated directly but an aqueous solution of Na 2 S 2 O 5 is added to form the bisulfite adduct of the ketone.
  • racemic bisulfite adduct crystallizes. The racemate is removed by filtration and the resulting mother liquor is typically 95 to 99 % enantiomeric excess (ee).
  • the acetone is removed in vacuo and isopropanol is added to give the crystalline bisulfite adduct with high enantiomeric excess.
  • This is treated with HCl and methanol with trimethylorthoformate as a water scavenger, to provide the dimethylketal.
  • the hydroxyl group is then methylated using NaOt-Bu and Me 2 SO 4 . Adding water and HCl to the reaction mixture provides the target ⁇ -methoxypyranone in about 96% ee.
  • Step 1 6- ⁇ [(1S,4S)-4-(2,5-dimethyl-1H-pyrrol-1-yl)-1-isopropylcyclopent-2-en-1-yl]carbonyl ⁇ -3-(trifluoromethyl)-5,6,7,8-tetrahydro-l,6-naphthyridine
  • the reaction solution was cooled to ⁇ 15°C and tetrahydronaphthyridine-HCl salt (670 g, 73.2wt% as free base equivalent, 2.42 mol) was added.
  • the temperature was increased to 23 °C and another portion of diisopropylethylamine (0.93 L, 5.34 mol) was added with cooling at ⁇ 25 °C over 15 min.
  • the mixture was aged for >1 h and was then diluted with 5% NaHCO 3 (16 L).
  • the product was extracted with ethyl acetate (EtOAc) (16 L).
  • EtOAc ethyl acetate
  • the organic phase was washed with water (10 L) and concentrated under vacuum with displacement of the EtOAc with methanol to a volume of 10 L.
  • the assay yield of the amide was quantitative (1.055 kg, 2.45 mol).
  • Step 2 (1S,4S)-4-isopropyl-4- ⁇ [3-(trifluorornetlzyl)-7,8-dilzydro-1,6-naphthyridin-6(5H)-yl]carboyzyl ⁇ cyclopent-2-en-1-amine
  • the amide (1.055 kg, 2.45 mol) in methanol (10 L) was added to hydroxylamine-HCl (1 kg, 14.4 mol), 50% hydroxylamine in water (1 L, 16.3 mol) and water (5 L).
  • the resulting slurry was heated to reflux (71 °C) and maintained at this temperature for 6 h.
  • the reaction solution was cooled to room temperature and the pH was adjusted to 11.0 with 10 N NaOH.
  • the reaction solution was diluted with water (12 L) and the product was extracted with chlorobenzene three times (14 L, 13L, and 13L). Each organic layer was washed once with the same water (10 L).
  • the organic layers containing product (0.79 assay kg, 2.24 mol, 92% yield) were combined and concentrated.
  • Step 3 (3S,4S)-N-((1S,4S)-4-isopropyl-4- ⁇ [3-(trifluoromethyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl]carbonyl ⁇ cyclopent-2-en-1-yl)-3-methoxytetrahydro-2H-pyran-4-amine
  • the amine dihydrochloride salt (777 g, 552 g as free base, 1.56 mol) was slurried in IPAc (3 L). The mixture was cooled in an ice bath and n -Bu 3 N (860 mL, 3.61 mol) was added followed by isopropanol (260 mL, 3.40 mol). Sodium triacetoxyborohydride (724 g, 3.42 mol) was added at 5°C. After 1 h, a solution of the methoxypyranone in IPAc (1.76 L of a 160 g/L solution, 2.17 mol) was added to the batch at 1°C. After 6 h, the mixture was partitioned between saturated aq.
  • the acetonitrile phase contained 654 g (1.4 mol, 90%) (35,45)-N-((1S,4S)-4-isopropyl-4- ⁇ [3-(trifluoromethyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)carbonyl ⁇ cyclopent-2-en-1-yl)-3-methoxytetrahydro-2H-pyran-4-amine.
  • the solvent was removed in vacuo to provide an oil that was used in the final hydrogenation step.
  • Step 4 ((1R,3S)-3-Isopropyl-3- ⁇ [3-(trifluoronzethyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl]carbonyl ⁇ cyclopentyl)[(3S,4S)-3-methoxytetrahydro-2H-pyran-4-yl]amine
  • the crude coupled cyclopentene of Step 3 (640 g) was diluted with methanol (3.2 L) and the solution was concentrated to an oil. Dilution with methanol (3.2 L) and concentration were repeated two additional times. After the final concentration the oil was diluted with methanol (6.4 L) and charged to an autoclave. The catalyst 5% Pd/C (256 g) was charged to the autoclave as a slurry in methanol (1.4 L). The hydrogenation (40 psi) was run overnight (18 h) at 25°C. The batch was filtered through solka floc ( ⁇ 1.5 in depth) in an 8 L sintered-glass funnel. The autoclave was rinsed with methanol (5.0 L) and this rinse was used to wash the filter cake.
  • Benzenesulfonate Salt The resulting oil from the Example 1 was dissolved in IPA (1.54 L) and transferred to crystallization flask. An IPA (2 X 385 mL) rinse was added to the batch. The solution was warmed to 56°C at which point benzenesulfonic acid (283 g, 1.79 mol) was added which resulted in an increase in temperature to 71°C. The solution was cooled to 60 °C and benzenesulfonate salt seed (1 g) was added. The thin slurry was aged for 30 min to develop a thick seed bed after which heptane (4.62 L) was added over 50 min.
  • the slurry was aged for 2 h at 65°C, then allowed to cool to room temperature overnight (-9 h).
  • the solids were filtered, washed with 2:1 heptane/ethanol (2 X 2.3 L, 2 mL/g free base), and dried under vacuum with a N 2 stream for 2 h.
  • the filtercake was broken up and further dried with N 2 /vacuum for ⁇ 48 h to afford 1.328 kg of the succinate salt (91.6 %).
  • the filtercake was dried by passing N 2 through it with vacuum for 3 h then the filtercake was broken up and further dried with N 2 /vacuum for approximately 48 h. After completion of drying the bulk drug was stored in a doubled polybag within a fiber drum to await milling. A total of 3.018 kg of the succinate salt (93.9 % yield) was obtained.
  • the solid aminocyclopentene methyl ester salt (1.076 kg, 6.059 mol) was dissolved in MeOH (3 L, 2M) at 20 °C under nitrogen.
  • Diisopropylethylamine (DIEA, 0.78 kg, 6.059 mol) was added followed by acetonyl acetone (0.711 kg, 6.241 mol).
  • the batch had an exotherm increasing the temperature to 32-35 °C.
  • the reaction mixture was then aged at 25 °C for 16 h.
  • the batch was diluted with IPAc (9-10 L) and washed with 10% NH 4 Cl (2 x 3 L) and 5% brine (2 x 3 L).
  • the IPA batch was dried over sodium sulfate, filtered, and concentrated to an oil.
  • LHMDS lithium hexamethyldisilazide
  • the organic layer was washed with 6% aq NH 4 Cl (10 L), 5% brine (2 x 10 L), and concentrated to an oil.
  • the air-sensitive alkylated pyrrole methyl ester (1419 g, 98% yield) was stored at 5-7 °C under nitrogen until saponified.
  • Step 4 (1S,4S)-4-(2,5-dimethyl-1H-pyrrol-1-yl)-1-isopropylcyclopent-2-ene-1-carboxylic acid
  • the alkylated pyrrole methyl ester (1.38 kg, 5.197 mol) was dissolved in MeOH (7.7 L). DI water (2.5 L) was added followed by 10N NaOH (2.08 L, 20.786 mol). The batch was then heated to 65 °C for 16 h. The batch was cooled to 10 °C. The product was crystallized by adjusting the pH to 4.5 with concd HCl. The slurry was aged for 1 h and DI water (15 L) was charged to the batch. The slurry was aged 18 h at 20-25°C.
  • Hexafluorophosphoric acid (980 mL, 60 wt% aqueous) was added to water (7.1 L) with cooling at 4 °C.
  • Sodium hydroxide (5 N, 2.0 L) was added slowly keeping the internal temperature below 15 °C.
  • the solution was then cooled to 0 °C.
  • Sodium hydroxide (5 N) was charged to a 2 L addition funnel and added concurrently with the TFPA/POCl 3 /DMF reaction mixture at a rate such that the internal temperature remained below 5 °C and the pH varied from 3.05 to 3.6 (approx. 3.2 during most of the addition).
  • the resulting yellow slurry was then aged for 60 min at ⁇ 0 °C.
  • Step 2 N-(tert-Butoxycarbonyl)-3-(trifluoromethyl)-5,6,7,8-tetrahydro-1,6-naphthyridine
  • N-BOC-4-piperidone (672 g) in THF (2.72 L) was charged to a solution of lithium bis(trimethylsilyl) amide (LHMDS) (3.55 L, 1.0 M solution in THF) in THF (3.7 L) at -12°C over 45 min.
  • LHMDS lithium bis(trimethylsilyl) amide
  • the reaction mixture was allowed to warm to room temperature. This mixture was added over 30 min to a slurry of CF 3 DT (1.17 kg) in THF (5.45 L) cooled to -24 °C. The reaction mixture was then aged for 2 h at ⁇ -20 °C. Acetic acid (295 mL) was added over 3 min.
  • the reaction mixture was warmed to 20°C over 1 h 15 min and ammonium acetate (741 g) was added in one portion.
  • the reaction mixture was warmed to 64 °C and aged for 2 h at this temperature.
  • the reaction mixture was cooled to room temperature then diluted with water (15.4 L) and methylcyclohexane (15.4 L).
  • the mixture was agitated, the stirring stopped, and the layers were allowed to settle.
  • Step 3 3-(trifluoromethyl)-5,6,7,8-tetrahydro-1,6-naphthyridine
  • the organic layer from the naphthyridine formation containing N-(tert-butoxycarbonyl)-3-(trifluoromethyl)-5,6,7,8-tetrahydro-1,6-naphthyridine (34.2 kg total weight containing 989 g of BOC naphthyridine) was concentrated to an oil.
  • the residue was diluted with methanol (6 L) and the solution was concentrated to an oil.
  • Methanol (6 L) was added to the residue and this solution was concentrated to 2.3 L.
  • the solution was diluted with methanol to a volume of 7.3 L and 4.58 M HCl in IPA (3.6 L) was added.
  • the solution was heated to 55 °C and aged for 1 h. After cooling to room temperature water (5 L) was added.
  • Step 1- tetrahyro-4H-pyran-4-one: A 22 L round-bottomed-flask equipped with a mechanical stirrer, thermocouple, and nitrogen inlet was charged with tetrahydro-4H-pyran-4-one (3.00 kg, 30.0 mol) and tripropylorthoformate (5.70 kg, 30.0 mol). The pump used for the transfer was flushed with chlorobenzene (300 mL) and the flush was added to the batch. The resulting solution was cooled in an ice bath to 5 °C. Amberlyst-15 (60 g), previously washed with DI water then propanol and dried, was added in one portion. The mixture was stirred at ambient temperature for 16 h.
  • the batch temperature was maintained between 122 and 125 °C during the distillation. After 16 h, GC assay indicated > 9:1 conversion.
  • the vacuum was increased to 50 mm Hg and the reaction was distilled to provide a 53 wt% solution of 3 (3.13 kg, 73 % yield) and chlorobenzene.
  • Step 2- 3,4-dihydroxy-tetrahydro-2-H-pyran-4-sulfonic acid, sodium salt A 50 L round-bottomed-flask equipped with a mechanical stirrer, nitrogen inlet and thermocouple was charged with acetone (12.7 L) and water (1.28 L). Hydroquinidine-1,4-phthalazinediyl diether (DHQD 2 PHAL, 54.8 g, 0.070 mol), potassium osmate dihydrate (12.95 g, 0.035 mol), and 4-methylmorpholine N-oxide monohydrate (NMO, 1.078 kg, 7.74 mol) were added sequentially to the solvent and the resulting solution was cooled to 0 °C.
  • DHQD 2 PHAL Hydroquinidine-1,4-phthalazinediyl diether
  • NMO 4-methylmorpholine N-oxide monohydrate
  • the propylenol ether (1.85 kg of a 54 wt % solution, 7.03 mol) was added over 7 h while maintaining a reaction temperature of about 0 °C.
  • the solids were removed by filtration and the filtrate was concentrated in vacuo to remove the acetone.
  • Isopropanol (28 L) was added over 3.5 h to provide a colorless slurry.
  • the solids were collected on a frit, rinsed with isopropanol (6 L) and dried in a vacuum oven to provide 958 g of 92 wt% (57 % isolated yield) product that was 97.2 % ee.
  • Step 3 4,4-dimethoxytetrahydro-2H pyran-3-ol: A 22 L round bottomed flask equipped with a mechanical stirrer, 5 L dropping funnel, nitrogen inlet and thermocouple was charged with bisulfite adduct (893 g of a 92 wt% solid, 4.06 mol)MeOH (8.1 L) and trimethylorthoformate (948 g, 8.93 mol). The resulting slurry was warmed to 50 °C and a 1.89 M solution of HCl in MeOH (2.48 L, 4.69 mol) was added via dropping funnel over 40 min.
  • the slurry was cooled to 7 °C and 50 wt% NaOH (340 mL) was added as a slow stream.
  • the solids were collected on a frit and the filtrate was solvent switched to toluene using a total of 12 L toluene.
  • the batch was concentrated to about 3 L then the solids were removed by filtration and the cake was rinsed with THF (2 L).
  • Step 4 (3R)-3-Methoxytetrahydro-4H-pyran-4-one:
  • NaOt-Bu (494 g, 5.14 mol) was added in one portion to provide a clear yellow solution.
  • the flask was immersed in an ice bath and Me 2 SO 4 (737 g, 5.84 mol) was added over 20 min maintaining an internal temp of below 36 °C. The cold bath was removed and the reaction mixture was aged for 4 h to provide a crude solution.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Claims (6)

  1. Die Verbindung der Formel (I):
    Figure imgb0025
    Figure imgb0026
  2. Verwendung der Verbindung der Formel (I) nach Anspruch 1 zur Herstellung eines Medikaments zur Behandlung, Verbesserung oder Verringerung des Risikos einer entzündlichen und immunregulatorischen Störung oder Erkrankung.
  3. Verwendung der Verbindung der Formel (I) nach Anspruch 1 zur Herstellung eines Medikaments zur Behandlung, Verbesserung oder Verringerung des Risikos von rheumatoider Arthritis.
  4. Eine pharmazeutische Zusammensetzung, die einen inerten Träger und eine Verbindung der Formel (I) nach Anspruch 1 enthält.
  5. Eine Verbindung der Formel (I) nach Anspruch 1 zur Verwendung in der Therapie.
  6. Eine Verbindung der Formel (I) nach Anspruch 1 zur Verwendung bei der Behandlung, Verbesserung oder Verringerung des Risikos einer entzündlichen und immunregulatorischen Störung oder Erkrankung oder von rheumatoider Arthritis.
EP04796120A 2003-10-27 2004-10-25 Salz eines Tetrahydropyranylcyclopentyltetrahydropyridopyridin-Derivats als CCR-2 Antagonisten Expired - Lifetime EP1682135B1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51473503P 2003-10-27 2003-10-27
PCT/US2004/035069 WO2005044264A1 (en) 2003-10-27 2004-10-25 Ccr-2 antagonist salt

Publications (3)

Publication Number Publication Date
EP1682135A1 EP1682135A1 (de) 2006-07-26
EP1682135A4 EP1682135A4 (de) 2009-11-25
EP1682135B1 true EP1682135B1 (de) 2011-07-27

Family

ID=34572774

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04796120A Expired - Lifetime EP1682135B1 (de) 2003-10-27 2004-10-25 Salz eines Tetrahydropyranylcyclopentyltetrahydropyridopyridin-Derivats als CCR-2 Antagonisten

Country Status (21)

Country Link
US (1) US7473696B2 (de)
EP (1) EP1682135B1 (de)
JP (1) JP4542550B2 (de)
KR (1) KR20060101476A (de)
CN (1) CN1870998B (de)
AT (1) ATE517622T1 (de)
AU (1) AU2004287416C1 (de)
BR (1) BRPI0415836A (de)
CA (1) CA2543201C (de)
CO (1) CO5690606A2 (de)
EC (1) ECSP066524A (de)
IL (1) IL175009A0 (de)
IS (1) IS8400A (de)
MA (1) MA28104A1 (de)
MX (1) MXPA06004647A (de)
NO (1) NO20062377L (de)
NZ (1) NZ546447A (de)
RU (1) RU2317295C1 (de)
UA (1) UA81365C2 (de)
WO (1) WO2005044264A1 (de)
ZA (1) ZA200602752B (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY129850A (en) 2002-04-29 2007-05-31 Merck Sharp & Dohme Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity
US20060030582A1 (en) * 2002-04-29 2006-02-09 Demartino Julie Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity
MXPA05005660A (es) 2002-11-27 2005-10-18 Incyte Corp Derivados de 3-aminopirrolidina como moduladores de receptores de quimocina.
US7393844B2 (en) * 2003-03-18 2008-07-01 Merck & Co., Inc. Tetrahydropyranyl cyclopentyl heterocyclic amide modulators of chemokine receptor activity
AR045875A1 (es) * 2003-10-27 2005-11-16 Merck & Co Inc Procedimiento para la preparacion del antagonista ccr-2
BRPI0417605B8 (pt) 2003-12-18 2021-05-25 Incyte Corp “n-[2-((3s)-3-{[4-hidróxi-4-(5-pirimidin-2- ilpiridin-2-il)ciclohexil]amino}-pirrolidin-1-il)-2- oxoetil]-3-(trifluor-metil)benzamida, ou um sal farmaceuticamente aceitável do mesmo e composição que o compreende”.
JP2007537264A (ja) 2004-05-11 2007-12-20 インサイト コーポレイション ケモカインレセプタのモジュレータとしての３−（４−ヘテロアリールシクロヘキシルアミノ）シクロペンタンカルボキサミド
GB0413605D0 (en) * 2004-06-17 2004-07-21 Addex Pharmaceuticals Sa Novel compounds
WO2006004741A2 (en) 2004-06-28 2006-01-12 Incyte Corporation 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
JP4116670B2 (ja) 2004-06-28 2008-07-09 インサイト コーポレイション ケモカイン受容体の調節剤としての３−アミノシクロペンタンカルボキサミド
CA2669917A1 (en) 2006-11-17 2008-05-22 Dawn M. George Aminopyrrolidines as chemokine receptor antagonists
US20090076065A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched mk-0812
US7741327B2 (en) 2008-04-16 2010-06-22 Hoffmann-La Roche Inc. Pyrrolidinone glucokinase activators
US8178689B2 (en) 2010-06-17 2012-05-15 Hoffman-La Roche Inc. Tricyclic compounds
WO2012125663A2 (en) * 2011-03-17 2012-09-20 Merck Sharp & Dohme Corp. Cyclohexane substituted amino cyclopentane derivatives as useful ccr2 antagonists
WO2013149376A1 (en) 2012-04-02 2013-10-10 Abbott Laboratories Chemokine receptor antagonists
EP2962691A4 (de) * 2013-02-28 2016-08-31 Santen Pharmaceutical Co Ltd Mittel zur prävention oder behandlung von erkrankungen der hinteren teile des auges mit einem tetrahydropyranyl-amino-cyclopentylcarbonyl-tetrahydropyridopyridin-derivat als wirkstoff
ES2904252T3 (es) 2015-05-21 2022-04-04 Chemocentryx Inc Moduladores de CCR2
CN118267479A (zh) 2017-09-25 2024-07-02 凯莫森特里克斯股份有限公司 使用趋化因子受体2(ccr2)拮抗剂和pd-1/pd-l1抑制剂的联合治疗
IL275898B2 (en) 2018-01-08 2025-05-01 Chemocentryx Inc Methods for treating solid tumors with CCR2 antagonists
US20190269664A1 (en) 2018-01-08 2019-09-05 Chemocentryx, Inc. Methods of treating solid tumors with ccr2 antagonists
CN112341350A (zh) * 2020-10-19 2021-02-09 江苏威奇达药业有限公司 酶法拆分γ-内酰胺后副产物的处理方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RO108347B1 (ro) * 1989-10-30 1994-04-28 Bellon Labor Sa Roger DERIVATI DE BENZO-(b)-NAFTIRIDIN-1,8 SI PROCEDEU DE PREPARARE A ACESTORA
GB9417249D0 (en) * 1994-08-26 1994-10-19 Wellcome Found A novel salt
JPH09291034A (ja) * 1996-02-27 1997-11-11 Yoshitomi Pharmaceut Ind Ltd 縮合ピリジン化合物およびその医薬としての用途
RU2174123C2 (ru) * 1996-10-28 2001-09-27 Новартис Аг Производные 8-арил-1,7-нафтиридина и фармацевтическая композиция, обладающая противовоспалительной активностью
US6312689B1 (en) * 1998-07-23 2001-11-06 Millennium Pharmaceuticals, Inc. Anti-CCR2 antibodies and methods of use therefor
FR2787790A3 (fr) * 1998-12-23 2000-06-30 Sanofi Sa Procede de preparation du (r)-(+)-3-{1°2-(4-benzoyl-2-(3,4- difluorophenyl)morpholin-2-yl)ethyl!-4-phenylpiperidin-4-yl} -1,1-dimethyluree, de ses sels, solvats et/ou hydrates
AU5473400A (en) 1999-06-11 2001-01-02 Merck & Co., Inc. Cyclopentyl modulators of chemokine receptor activity
EP1318811B1 (de) * 2000-08-17 2006-08-30 Merck & Co., Inc. Cyclopentylmodulatoren der chemokin-rezeptor-aktivität
CZ20031315A3 (cs) * 2000-11-28 2004-04-14 Pfizer Products Inc. Soli isothiazolkarboxamidu a jejich použití jako prostředků proti hyperproliferaci
EP1461040B1 (de) * 2001-11-29 2006-03-15 Pfizer Products Inc. Succinate des 5,8,14-triazatetracyclo[10.3.1.0 2,11 .0 4,9 ]-hexadeca-2(11),3,5,7,9,-pentaens und pharmazeutische zusammensetzungen
GEP20063872B (en) * 2001-12-12 2006-07-10 Pfizer Prod Inc Salt forms of e-2-methoxy-n-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quina-zolin-6-yl}-allyl)-acetamide and method of production
JP4459807B2 (ja) * 2002-04-29 2010-04-28 メルク エンド カムパニー インコーポレーテッド テトラヒドロピラニルシクロペンチルテトラヒドロイソキノリン系のケモカイン受容体活性調節剤
EP1501507B1 (de) * 2002-04-29 2008-05-28 Merck & Co., Inc. Tetrahydropyranyl-cyclopentyl-tetrahydropyridopyridin-modulatoren der chemokin-rezeptor-aktivität
MY129850A (en) 2002-04-29 2007-05-31 Merck Sharp & Dohme Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity
AR045875A1 (es) * 2003-10-27 2005-11-16 Merck & Co Inc Procedimiento para la preparacion del antagonista ccr-2

Also Published As

Publication number Publication date
ZA200602752B (en) 2007-08-29
US7473696B2 (en) 2009-01-06
JP4542550B2 (ja) 2010-09-15
EP1682135A1 (de) 2006-07-26
MA28104A1 (fr) 2006-08-01
JP2007509940A (ja) 2007-04-19
CN1870998A (zh) 2006-11-29
KR20060101476A (ko) 2006-09-25
BRPI0415836A (pt) 2007-01-02
AU2004287416A1 (en) 2005-05-19
ATE517622T1 (de) 2011-08-15
AU2004287416C1 (en) 2010-09-09
NO20062377L (no) 2006-05-24
IL175009A0 (en) 2006-08-20
CA2543201A1 (en) 2005-05-19
ECSP066524A (es) 2006-10-10
RU2317295C1 (ru) 2008-02-20
CA2543201C (en) 2010-12-21
UA81365C2 (en) 2007-12-25
CN1870998B (zh) 2010-10-20
WO2005044264A1 (en) 2005-05-19
MXPA06004647A (es) 2006-06-27
NZ546447A (en) 2009-02-28
EP1682135A4 (de) 2009-11-25
US20070135474A1 (en) 2007-06-14
IS8400A (is) 2006-04-06
CO5690606A2 (es) 2006-10-31
AU2004287416B2 (en) 2009-11-19

Similar Documents

Publication Publication Date Title
EP1682135B1 (de) Salz eines Tetrahydropyranylcyclopentyltetrahydropyridopyridin-Derivats als CCR-2 Antagonisten
US9126906B2 (en) Asymmetric synthetic processes for the preparation of aminosulfone compounds
US11370739B2 (en) Sacubitril intermediate and preparation method thereof
CN100545145C (zh) 用于制备1,2-二氨基化合物的不使用叠氮化物的方法
AU2004287810B2 (en) Process for the preparation of CCR-2 antagonist
JP2019210273A (ja) エドキサバンの製造方法
AU8680598A (en) Alpha 1a adrenergic receptor antagonist
US5962724A (en) High enantio-selective process for producing pure enantiomeric cyclopentane and cyclopentene-(β)-amino acids
US7232907B2 (en) Process for production of naphthyridine-3-carboxylic acid derivatives
US20130197229A1 (en) Method of making azaindazole derivatives
KR20040079324A (ko) 4-아미노메틸-3-알콕시이미노피롤리딘 메탄설폰산염의신규한 제조 방법
EP2448916B1 (de) Herstellung von trans-4-aminocyclopentan-2-en-1-carboxylsäurederivaten
EP4276101B1 (de) Verfahren zur herstellung eines pyrrolopyridinderivats
US20040236118A1 (en) Pyrrolidine derivatives and method of synthesizing these
JP2019526554A (ja) Ｎｅｐ阻害剤合成のための新規な方法および中間体
USH1737H (en) 7-oxabicycloheptane carboxylic acid prostaglandin analog intermediates useful in the preparation of anti-thrombotic and anti-vasospastic compounds and method for preparing same
HK1099208A (zh) Ccr-2拮抗劑鹽

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060529

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: HR LT LV

RAX Requested extension states of the european patent have changed

Extension state: LT

Payment date: 20060529

Extension state: LV

Payment date: 20060529

Extension state: HR

Payment date: 20060529

A4 Supplementary search report drawn up and despatched

Effective date: 20091027

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 471/04 20060101ALI20091016BHEP

Ipc: A61P 37/02 20060101ALI20091016BHEP

Ipc: A61P 29/00 20060101ALI20091016BHEP

Ipc: A61K 31/4375 20060101AFI20050526BHEP

Ipc: A61P 43/00 20060101ALI20091016BHEP

Ipc: A61P 37/00 20060101ALI20091016BHEP

17Q First examination report despatched

Effective date: 20091222

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: MERCK SHARP & DOHME CORP.

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RTI1 Title (correction)

Free format text: SALT OF A TETRAHYDROPYRANYL CYCLOPENTYL TETRAHYDROPYRIDOPYRIDINE DERIVATIVE AS CCR2-ANTAGONIST

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: HR LT LV

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: SERVOPATENT GMBH

REG Reference to a national code

Ref country code: NL

Ref legal event code: T3

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602004033695

Country of ref document: DE

Effective date: 20110915

LTIE Lt: invalidation of european patent or patent extension

Effective date: 20110727

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 517622

Country of ref document: AT

Kind code of ref document: T

Effective date: 20110727

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20111128

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110727

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110727

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110727

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110727

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110727

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20111028

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110727

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110727

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110727

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110727

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110727

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110727

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110727

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20111031

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110727

26N No opposition filed

Effective date: 20120502

REG Reference to a national code

Ref country code: CH

Ref legal event code: PFUS

Owner name: SCHERING CORPORATION, US

Free format text: FORMER OWNER: MERCK SHARP + DOHME CORP., US

Ref country code: CH

Ref legal event code: PFA

Owner name: MERCK SHARP & DOHME CORP.

Free format text: SCHERING CORPORATION#2000 GALLOPING HILL ROAD#KENILWORTH, NJ 07033 (US) -TRANSFER TO- MERCK SHARP & DOHME CORP.#126 EAST LINCOLN AVENUE#RAHWAY, NEW JERSEY 07065 (US)

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602004033695

Country of ref document: DE

Effective date: 20120502

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

Free format text: REGISTERED BETWEEN 20120802 AND 20120808

REG Reference to a national code

Ref country code: NL

Ref legal event code: SD

Effective date: 20120828

REG Reference to a national code

Ref country code: NL

Ref legal event code: TD

Effective date: 20120924

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20111025

REG Reference to a national code

Ref country code: DE

Ref legal event code: R081

Ref document number: 602004033695

Country of ref document: DE

Owner name: MERCK SHARP & DOHME CORP., US

Free format text: FORMER OWNER: MERCK SHARP & DOHME CORP., RAHWAY, US

Effective date: 20121213

Ref country code: DE

Ref legal event code: R082

Ref document number: 602004033695

Country of ref document: DE

Representative=s name: ABITZ & PARTNER, DE

Effective date: 20121213

Ref country code: DE

Ref legal event code: R081

Ref document number: 602004033695

Country of ref document: DE

Owner name: MERCK SHARP & DOHME CORP., US

Free format text: FORMER OWNER: MERCK & CO., INC., WHITEHOUSE STATION, US

Effective date: 20110726

Ref country code: DE

Ref legal event code: R081

Ref document number: 602004033695

Country of ref document: DE

Owner name: SCHERING CORPORATION, US

Free format text: FORMER OWNER: MERCK SHARP & DOHME CORP., RAHWAY, US

Effective date: 20121213

Ref country code: DE

Ref legal event code: R081

Ref document number: 602004033695

Country of ref document: DE

Owner name: SCHERING CORPORATION, US

Free format text: FORMER OWNER: MERCK & CO., INC., WHITEHOUSE STATION, US

Effective date: 20110726

Ref country code: DE

Ref legal event code: R081

Ref document number: 602004033695

Country of ref document: DE

Owner name: MERCK SHARP & DOHME CORP., RAHWAY, US

Free format text: FORMER OWNER: MERCK & CO., INC., WHITEHOUSE STATION, N.J., US

Effective date: 20110726

Ref country code: DE

Ref legal event code: R081

Ref document number: 602004033695

Country of ref document: DE

Owner name: MERCK SHARP & DOHME CORP., RAHWAY, US

Free format text: FORMER OWNER: MERCK SHARP & DOHME CORP., RAHWAY, N.J., US

Effective date: 20121213

Ref country code: DE

Ref legal event code: R082

Ref document number: 602004033695

Country of ref document: DE

Representative=s name: ABITZ & PARTNER PATENTANWAELTE MBB, DE

Effective date: 20121213

REG Reference to a national code

Ref country code: FR

Ref legal event code: TP

Owner name: SCHERING CORPORATION, US

Effective date: 20130318

Ref country code: FR

Ref legal event code: CD

Owner name: SCHERING CORPORATION, US

Effective date: 20130319

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20111107

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 602004033695

Country of ref document: DE

Representative=s name: ABITZ & PARTNER, DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20111025

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20111027

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 602004033695

Country of ref document: DE

Representative=s name: ABITZ & PARTNER, DE

Effective date: 20130514

Ref country code: DE

Ref legal event code: R081

Ref document number: 602004033695

Country of ref document: DE

Owner name: MERCK SHARP & DOHME CORP., US

Free format text: FORMER OWNER: SCHERING CORPORATION, RAHWAY, US

Effective date: 20130514

Ref country code: DE

Ref legal event code: R081

Ref document number: 602004033695

Country of ref document: DE

Owner name: MERCK SHARP & DOHME CORP., RAHWAY, US

Free format text: FORMER OWNER: SCHERING CORPORATION, RAHWAY, US

Effective date: 20130514

Ref country code: DE

Ref legal event code: R082

Ref document number: 602004033695

Country of ref document: DE

Representative=s name: ABITZ & PARTNER PATENTANWAELTE MBB, DE

Effective date: 20130514

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110727

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110727

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20131029

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20131010

Year of fee payment: 10

REG Reference to a national code

Ref country code: NL

Ref legal event code: V1

Effective date: 20150501

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20141031

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20141031

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150501

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20150924

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20150924

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20151030

Year of fee payment: 12

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602004033695

Country of ref document: DE

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20161025

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20170630

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20161025

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20161102

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170503